Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 12/20 | 0.35 |
| ▸ | ITGAV | P06756 | 2/20 | 0.34 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 4/20 | 0.33 |
| ▸ | MMP3 | P08254 | 3/20 | 0.33 |
| ▸ | MMP7 | P09237 | 3/20 | 0.33 |
| ▸ | MMP9 | P14780 | 3/20 | 0.33 |
| ▸ | MMP8 | P22894 | 3/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1072401 | 1.00 | MMP13 (0.35) | MMP13ITGAVITGB6EPHX1PRMT5 | |
| SCHEMBL3304630 | 0.87 | REN (0.31) | MMP13MMP1 | |
| SCHEMBL3309650 | 0.87 | REN (0.31) | MMP13MMP1 | |
| SCHEMBL1073190 | 0.86 | REN (0.33) | MMP13MMP1 | |
| SCHEMBL12963756 | 0.82 | REN (0.34) | — | |
| SCHEMBL1068683 | 0.81 | F2 (0.34) | MMP13MMP1 | |
| SCHEMBL31063148 | 0.80 | PRMT5 (0.43) | EPHX1PRMT5WDR77PIK3CD | |
| SCHEMBL31063417 | 0.80 | PRMT5 (0.43) | EPHX1PRMT5WDR77PIK3CD | |
| SCHEMBL20292517 | 0.80 | ALDH1A1 (0.33) | — | |
| SCHEMBL1072629 | 0.80 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | RRP1B, ZC3HAV1, RNASE1 | MMP13 422/4885ITGAV 2815/4885ITGB6 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.